JPWO2019170750A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019170750A5 JPWO2019170750A5 JP2020547036A JP2020547036A JPWO2019170750A5 JP WO2019170750 A5 JPWO2019170750 A5 JP WO2019170750A5 JP 2020547036 A JP2020547036 A JP 2020547036A JP 2020547036 A JP2020547036 A JP 2020547036A JP WO2019170750 A5 JPWO2019170750 A5 JP WO2019170750A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- treating
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 111
- 238000000034 method Methods 0.000 claims description 75
- 150000003839 salts Chemical class 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 3
- 229910052805 deuterium Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910005965 SO 2 Inorganic materials 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- -1 cyano, hydroxy Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639650P | 2018-03-07 | 2018-03-07 | |
| US62/639,650 | 2018-03-07 | ||
| PCT/EP2019/055576 WO2019170750A1 (en) | 2018-03-07 | 2019-03-06 | Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021517134A JP2021517134A (ja) | 2021-07-15 |
| JP2021517134A5 JP2021517134A5 (https=) | 2022-03-15 |
| JPWO2019170750A5 true JPWO2019170750A5 (https=) | 2022-03-15 |
| JP7396991B2 JP7396991B2 (ja) | 2023-12-12 |
Family
ID=65894963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547036A Active JP7396991B2 (ja) | 2018-03-07 | 2019-03-06 | 癌、潰瘍性大腸炎、及び関連する炎症性疾患の処置に有用な方法、並びにイソインドリン－１，３－ジオン及びイソインドールプロドラッグの組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11639332B2 (https=) |
| EP (1) | EP3762365B1 (https=) |
| JP (1) | JP7396991B2 (https=) |
| AR (1) | AR114666A1 (https=) |
| AU (1) | AU2019229583B2 (https=) |
| CA (1) | CA3093196A1 (https=) |
| ES (1) | ES2987705T3 (https=) |
| MA (1) | MA52266A (https=) |
| MX (1) | MX2020009288A (https=) |
| TW (1) | TW202000646A (https=) |
| WO (1) | WO2019170750A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118370746A (zh) * | 2024-04-25 | 2024-07-23 | 江苏省中医院 | 马尿酸在制备溃疡性结肠炎治疗药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2472965A (en) | 1949-06-14 | Metallized tetrakisazo dyes | ||
| US3951943A (en) | 1974-03-18 | 1976-04-20 | Chemetron Corporation | Coupling process in the preparation of disazo diimides |
| EP0856562A1 (en) | 1997-01-31 | 1998-08-05 | Hodogaya Chemical Co Ltd | Recording liquid and novel metal complex compound contained therein |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| JPWO2002001667A1 (ja) * | 2000-06-29 | 2004-01-08 | 日本化薬株式会社 | 色素増感光電変換素子 |
| US7842662B2 (en) * | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
| AU2008270363A1 (en) * | 2007-06-29 | 2009-01-08 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Targeting diazo prodrugs for the treatment of gastrointestinal diseases |
| CA2718601A1 (en) | 2008-03-27 | 2009-10-01 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| WO2012083153A1 (en) * | 2010-12-16 | 2012-06-21 | Nektar Therapeutics | Oligomer-containing apremilast moiety compounds |
| MX347928B (es) | 2011-01-10 | 2017-05-19 | Celgene Corp | Derivados de fenetilsulfona isoindolina y su uso. |
-
2019
- 2019-03-06 WO PCT/EP2019/055576 patent/WO2019170750A1/en not_active Ceased
- 2019-03-06 JP JP2020547036A patent/JP7396991B2/ja active Active
- 2019-03-06 US US16/970,598 patent/US11639332B2/en active Active
- 2019-03-06 CA CA3093196A patent/CA3093196A1/en active Pending
- 2019-03-06 MX MX2020009288A patent/MX2020009288A/es unknown
- 2019-03-06 TW TW108107510A patent/TW202000646A/zh unknown
- 2019-03-06 ES ES19712695T patent/ES2987705T3/es active Active
- 2019-03-06 MA MA052266A patent/MA52266A/fr unknown
- 2019-03-06 AU AU2019229583A patent/AU2019229583B2/en active Active
- 2019-03-06 EP EP19712695.6A patent/EP3762365B1/en active Active
- 2019-03-06 AR ARP190100547A patent/AR114666A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007119562A (ru) | Тетрациклические производные индолов в качестве противовирусных агентов | |
| JP2013501731A5 (https=) | ||
| MX2008010187A (es) | Tratamiento de distrofia muscular de duchenne. | |
| RU2009144538A (ru) | Новые циклические пептидные соединения | |
| JP2006524222A5 (https=) | ||
| JP2009507909A5 (https=) | ||
| JP2012507566A5 (https=) | ||
| CA2553269A1 (en) | Quinoline derivatives and use thereof as mycobacterial inhibitors | |
| JP2009524675A5 (https=) | ||
| JP2017531041A5 (https=) | ||
| JP2012516900A5 (https=) | ||
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| RU2008139195A (ru) | Замещенные арилсульфанамиды как противовирусные средства | |
| JP2011513475A5 (https=) | ||
| JP2010536842A5 (https=) | ||
| CA2617817A1 (en) | Thiazole derivatives for treating or preventing sleep disorders | |
| RU2002130247A (ru) | Производные оксадиазола, обладающие противоопухолевым действием | |
| CA2584303A1 (en) | Novel heterocycles | |
| JPWO2019170750A5 (https=) | ||
| JP2021517134A5 (https=) | ||
| JP2003516994A5 (https=) | ||
| RU2009139073A (ru) | Соединения хинолина для лечения нарушений, которые реагируют на модуляцию рецептора серотонина 5-нт6 | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| JP2013525290A5 (https=) | ||
| CA2552855A1 (en) | Azabicyclooctan-3-one derivatives and use thereof |